
"I saw a patient who's no longer a patient, and there's nothing better than that."
Where I see patients (1)
Selected research
-
Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.
British journal of haematology
-
Innate immune mechanisms hijacked by leukemia-initiating stem cells for selective advantage and immune evasion in Ptpn11-associated JMML.
Cell reports
-
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.
bioRxiv : the preprint server for biology
Clinical trials
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...
Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...
Recruiting
More about this studyThe Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in...
The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confiden...
Recruiting
More about this studyInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or...
The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. A one-sided lower 95% Agresti-Coull confidence limit will be calculated.
Recruiting
More about this studyContact me
Soothing the soul
Our music therapy program nurtures patients with bedside serenades, rap workshops and more.
Find out more
